Trial Profile
A Phase II Study of the Peroxisome Proliferator-Activated Receptor Gamma Agonist, Efatutazone in Patients With Previously Treated, Unresectable Myxoid Liposarcoma
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 20 Feb 2024
Price :
$35
*
At a glance
- Drugs Efatutazone (Primary)
- Indications Myxoid liposarcoma
- Focus Therapeutic Use
- 05 Jun 2023 Status changed from active, no longer recruiting to completed.
- 31 Aug 2018 Planned primary completion date changed from 1 Aug 2018 to 1 Oct 2018.
- 08 Jun 2018 Status changed from recruiting to active, no longer recruiting.